J
Julie A. Vendrell
Researcher at University of Montpellier
Publications - 49
Citations - 1931
Julie A. Vendrell is an academic researcher from University of Montpellier. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 20, co-authored 45 publications receiving 1601 citations. Previous affiliations of Julie A. Vendrell include Claude Bernard University Lyon 1 & University of Lyon.
Papers
More filters
Journal ArticleDOI
p53 Acts as a Safeguard of Translational Control by Regulating Fibrillarin and rRNA Methylation in Cancer
Virginie Marcel,Virginie Marcel,Sandra E. Ghayad,Sandra E. Ghayad,Stephane Belin,Stephane Belin,Gabriel Therizols,Gabriel Therizols,Anne Pierre Morel,Anne Pierre Morel,Eduardo Solano-Gonzàlez,Julie A. Vendrell,Sabine Hacot,Sabine Hacot,Hichem C. Mertani,Hichem C. Mertani,Marie Alexandra Albaret,Marie Alexandra Albaret,Jean-Christophe Bourdon,Lee B. Jordan,Alastair M. Thompson,Yasmine Tafer,Yasmine Tafer,Rong Cong,Philippe Bouvet,Jean Christophe Saurin,Jean Christophe Saurin,Frédéric Catez,Frédéric Catez,Anne-Catherine Prats,Alain Puisieux,Alain Puisieux,Jean-Jacques Diaz,Jean-Jacques Diaz +33 more
TL;DR: It is shown that p53 represses expression of the rRNA methyl-transferase fibrillarin (FBL) by binding directly to FBL, and acts as a safeguard of protein synthesis by regulating FBL and the subsequent quality and intrinsic activity of ribosomes.
Journal ArticleDOI
Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach
Sengül Tozlu,Igor Girault,Sophie Vacher,Julie A. Vendrell,Catherine Andrieu,F. Spyratos,Pascale A. Cohen,Rosette Lidereau,Ivan Bièche +8 more
TL;DR: Surprisingly, only a small proportion of the 51 genes identified in breast tumor biopsy specimens were confirmed to be ERalpha-regulated and/or E2-regulated in vitro (cultured cell lines) and better delineate the role of ERalpha in breast cancer.
Journal ArticleDOI
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Sandra E. Ghayad,Julie A. Vendrell,Sabrina Ben Larbi,Charles Dumontet,Ivan Bièche,Pascale A. Cohen +5 more
TL;DR: In conclusion, the combination of MAPK and PI3K inhibitors represents a promising strategy to overcome endocrine therapy resistance in ER+ breast cancer patients.
Journal ArticleDOI
ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion.
Julie A. Vendrell,Aurélie Thollet,Nhan Trung Nguyen,Sandra E. Ghayad,Stéphanie Vinot,Ivan Bièche,Evelyne Grisard,Véronique Josserand,Jean-Luc Coll,Pierre Roux,Laura Corbo,Isabelle Treilleux,Ruth Rimokh,Pascale A. Cohen +13 more
TL;DR: Findings indicate that ZNF217 mRNA expression may represent a novel prognostic biomarker in breast cancer and therapeutic targeting of Z NF217 of the TGF-β signaling pathway may benefit the subset of patients whose tumors express high levels of ZNF 217.
Journal ArticleDOI
Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications
Mélanie Nugoli,Paul Chuchana,Julie A. Vendrell,Béatrice Orsetti,Lisa Ursule,Catherine Nguyen,Daniel Birnbaum,Emmanuel J. P. Douzery,Pascale A. Cohen,Pascale A. Cohen,Charles Theillet +10 more
TL;DR: It is proposed that MCF-7, and possibly the breast tumor it was derived from, evolved in a node like pattern, rather than according to a linear progression model, and could represent an interesting model for genetic evolution of breast tumors.